The company has just placed an order for 3000 bottles of emerging cannabinoid oil, which appear under the brand name Incannex.

These products will be distributed under the Australian Special Access Scheme, which means the unregistered medicinal oils are prescribed on a case-by-case basis.

This 3000-strong order is considered the first of many for Impression, who believe there's enough stock available to support future supply.

The purchase order follows the launch of three new cannabinoid products under the Impression Healthcare banner. The emerging Nutralesic, Inflammex and Releafia brands will provide the market with cannabinoid oils that contain varying levels of CBD and THC.

"The new brands open new avenues for sales as the company now has a product suite that covers the majority of the addressable market for legal cannabinoid products in Australia," Impression said in today's announcement.

"Not only will these products facilitate increased sales, but they will enable IHL to assess patient feedback to refine future products," they continued.

In addition to the cannabinoid oils, the company is also developing a soft gel capsule form of CBD for elderly patients. Impression is also undertaking clinical trials to develop four new pipeline products.

According to the company, these new medicinal cannabis offerings are unique and use CBD oil to treat common issues like gum disease, sleep apnoea, concussions, and Temporomandibular Joint Dysfunction (TMD).

Impression shares soared 8.33 per cent on the back of this morning's news. Stock is trading for 6.5 cents each at 12:42 pm AEDT.

CBD Vape Oil

Cbd Isolate, Cbd Oil, Cbd Wax, Cannabidiol Isolate, Cbd Extract - Hongbao,